A phase II/III, open-label, randomized trial of pembrolizumab + olaparib vs. pembrolizumab + chemotherapy after induction with pembrolizumab plus chemotherapy in locally recurrent inoperable or metastatic triple-negative breast cancer: KEYLYNK-009 Meeting Abstract
| Authors: | Rugo, H. S.; Llombart Cussac, A.; André, F.; Robson, M.; Saji, S.; Harbeck, N.; Schmid, P.; Cescon, D. W.; Seok Ahn, J.; Nanda, R.; Fan, L.; Mejia, J.; Karantza, V.; Bardia, A. |
| Abstract Title: | A phase II/III, open-label, randomized trial of pembrolizumab + olaparib vs. pembrolizumab + chemotherapy after induction with pembrolizumab plus chemotherapy in locally recurrent inoperable or metastatic triple-negative breast cancer: KEYLYNK-009 |
| Meeting Title: | ESMO Virtual Congress 2020 |
| Journal Title: | Annals of Oncology |
| Volume: | 31 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2020 Sep 19-21/Oct 16-18 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2020-09-01 |
| Start Page: | S392 |
| Language: | English |
| ACCESSION: | WOS:000573469100356 |
| DOI: | 10.1016/j.annonc.2020.08.458 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 356TiP -- Source: Wos |
